PMP22 protein

Four grams a day of vitamin C wasn't beneficial in type 1A Charcot-Marie-Tooth disease, but the trial yielded advances in CMT trial design

posted on June 27, 2013 - 10:15am
An MDA-supported trial of high-dose ascorbic acid (vitamin C) in the type 1A form of Charcot-Marie-Tooth disease (CMT) (CMT1A) did not find a benefit for this treatment, although it appeared safe and was generally well-tolerated. There were no serious adverse events judged to be related to the study drug.

New content is being added every day. Please check back again.